4782.0000 -23.00 (-0.48%)
NSE Jun 19, 2025 15:31 PM
Volume: 79,205
 

4782.00
-0.48%
HDFC Securities
The fourth quarter is seasonally weak for ALKEM, and 4QFY17 was no different. The top-line grew by a mere 9.5% YoY, affected by channel de-stocking and seasonality. EBITDA margin at 11.9% and PAT at ~1.4bn also missed our estimates by ~370bps and 16% respectively.
Alkem Laboratories L.. has an average target of 5278.50 from 2 brokers.
More from Alkem Laboratories Ltd.
Recommended